Open access
Oct 2026
Paxalisib with Trastuzumab for HER2-Positive Metastatic Breast Cancer with Active Brain Metastases: A Phase II Trial with Integrated Plasma and CSF ctDNA Analyses
Abstract Purpose: Human epidermal growth factor receptor 2 (HER2)–positive breast cancer brain metastases (BCBM) frequently harbor PI3K/AKT/mTOR alterations. Preclinical HER2+ BCBM models demonstrated durable tumor regression with dual PI3K and mTOR inhibition. Our phase II trial evaluated paxalisib, a brain-penetrant...
E. Seguí, Jorge Gómez Tejeda Zañudo, N. Graham et al.
· Cancer Research Communicatio... · 0 citations